StockIQ.techDaiichi Sankyo Company, Limited (4568.T) Stock Analysis
Free AI-powered analysis and research for Daiichi Sankyo Company, Limited stock
Sector: Healthcare
4568.T snapshot
Data as of 2 Nov 2026 close. Updated daily.
Daiichi Sankyo Company, Limited scores 94/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 33% of its 52-week range, down 14.2% over the past year. Latest reported figures show a profit margin of 10.9%, return on equity of 14.8% and revenue growth of +21.1%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- Strong Revenue Growth (21.1%): +8
- Good Profit Margin (10.9%): +5
- Low Debt (0.29 D/E): +8
- Strong Liquidity (2.92 Current Ratio): +8
- Above MA200: +4
- Underperforming (-14.2% over 1 year): -5
- High Volume (1.7x): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full 4568.T report
Daiichi Sankyo Company, Limited (4568.T) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze 4568.T Now →📰 Latest Update
Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
Fri, October 30, 2026 at 5:26 AM UTC 2 min read
Daiichi Sankyo reported a rise in first-half profits, driven by strong sales of its cancer drugs. This growth highlights the company's successful product pipeline and potential for future revenue increases, making it an attractive option for investors seeking exposure to the oncology market. Following the announcement, shares of Daiichi Sankyo saw an uptick, reflecting positive market sentiment.